KR960029319A - 4-아미노벤조일구아니딘 유도체 - Google Patents
4-아미노벤조일구아니딘 유도체 Download PDFInfo
- Publication number
- KR960029319A KR960029319A KR1019960002014A KR19960002014A KR960029319A KR 960029319 A KR960029319 A KR 960029319A KR 1019960002014 A KR1019960002014 A KR 1019960002014A KR 19960002014 A KR19960002014 A KR 19960002014A KR 960029319 A KR960029319 A KR 960029319A
- Authority
- KR
- South Korea
- Prior art keywords
- general formula
- group
- diaminomethylene
- physiologically acceptable
- methylsulfonylbenzoamide
- Prior art date
Links
- CNRCFIFMZGXXRA-UHFFFAOYSA-N 4-amino-n-(diaminomethylidene)benzamide Chemical class NC(=N)NC(=O)C1=CC=C(N)C=C1 CNRCFIFMZGXXRA-UHFFFAOYSA-N 0.000 title claims abstract 3
- 150000001875 compounds Chemical class 0.000 claims abstract 13
- 150000003839 salts Chemical class 0.000 claims abstract 9
- 229910052799 carbon Inorganic materials 0.000 claims abstract 4
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims abstract 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims abstract 2
- 125000000217 alkyl group Chemical group 0.000 claims abstract 2
- 125000002947 alkylene group Chemical group 0.000 claims abstract 2
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims abstract 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims abstract 2
- 125000004430 oxygen atom Chemical group O* 0.000 claims abstract 2
- 125000003367 polycyclic group Chemical group 0.000 claims abstract 2
- 125000004434 sulfur atom Chemical group 0.000 claims abstract 2
- 238000011282 treatment Methods 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- 239000007788 liquid Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- VUKXXOLBVCEOPX-UHFFFAOYSA-N 1-amino-1-benzoylguanidine Chemical class NC(=N)N(N)C(=O)C1=CC=CC=C1 VUKXXOLBVCEOPX-UHFFFAOYSA-N 0.000 claims 1
- VWAFLEGBBUPXFC-UHFFFAOYSA-N 3-methylsulfonyl-N',N'-di(propan-2-yl)benzohydrazide Chemical compound C(C)(C)N(NC(C1=CC=CC(=C1)S(=O)(=O)C)=O)C(C)C VWAFLEGBBUPXFC-UHFFFAOYSA-N 0.000 claims 1
- ONZBYQNJDSNGFG-UHFFFAOYSA-N 4-(3-chloroanilino)-n-(diaminomethylidene)-2-methyl-5-methylsulfonylbenzamide Chemical compound C1=C(C(=O)N=C(N)N)C(C)=CC(NC=2C=C(Cl)C=CC=2)=C1S(C)(=O)=O ONZBYQNJDSNGFG-UHFFFAOYSA-N 0.000 claims 1
- XGOQYULDBOHWAJ-UHFFFAOYSA-N 4-anilino-n-(diaminomethylidene)-2-methyl-5-methylsulfonylbenzamide Chemical compound C1=C(C(=O)N=C(N)N)C(C)=CC(NC=2C=CC=CC=2)=C1S(C)(=O)=O XGOQYULDBOHWAJ-UHFFFAOYSA-N 0.000 claims 1
- 206010002383 Angina Pectoris Diseases 0.000 claims 1
- 206010061216 Infarction Diseases 0.000 claims 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 230000006793 arrhythmia Effects 0.000 claims 1
- 206010003119 arrhythmia Diseases 0.000 claims 1
- 239000003638 chemical reducing agent Substances 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 230000007574 infarction Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- PWGFTLPNGZRQHY-UHFFFAOYSA-N n-(diaminomethylidene)-2-ethyl-5-methylsulfonyl-4-piperidin-1-ylbenzamide Chemical compound C1=C(C(=O)N=C(N)N)C(CC)=CC(N2CCCCC2)=C1S(C)(=O)=O PWGFTLPNGZRQHY-UHFFFAOYSA-N 0.000 claims 1
- KVSBIOOFQZIJHB-UHFFFAOYSA-N n-(diaminomethylidene)-2-methyl-5-methylsulfonyl-4-(pyrimidin-2-ylamino)benzamide Chemical compound C1=C(C(=O)N=C(N)N)C(C)=CC(NC=2N=CC=CN=2)=C1S(C)(=O)=O KVSBIOOFQZIJHB-UHFFFAOYSA-N 0.000 claims 1
- LOKHIJHQTYHWHJ-UHFFFAOYSA-N n-(diaminomethylidene)-2-methyl-5-methylsulfonyl-4-piperidin-1-ylbenzamide Chemical compound C1=C(C(=O)N=C(N)N)C(C)=CC(N2CCCCC2)=C1S(C)(=O)=O LOKHIJHQTYHWHJ-UHFFFAOYSA-N 0.000 claims 1
- SPISUERGLFPOOX-UHFFFAOYSA-N n-(diaminomethylidene)-4-[di(propan-2-yl)amino]-2-methyl-5-methylsulfonylbenzamide Chemical compound CC(C)N(C(C)C)C1=CC(C)=C(C(=O)N=C(N)N)C=C1S(C)(=O)=O SPISUERGLFPOOX-UHFFFAOYSA-N 0.000 claims 1
- AJDQRQQNNLZLPM-UHFFFAOYSA-N n-(diaminomethylidene)benzamide Chemical compound NC(N)=NC(=O)C1=CC=CC=C1 AJDQRQQNNLZLPM-UHFFFAOYSA-N 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 abstract 1
- 230000003288 anthiarrhythmic effect Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000003834 intracellular effect Effects 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
- C07C317/48—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmacology & Pharmacy (AREA)
- Cardiology (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Pyridine Compounds (AREA)
Abstract
본 발명은 하기 일반식(Ⅰ)으로 표시되는 4-아미노벤조일구아니딘 유도체 및 이의 생리학적으로 허용 가능한 염을 제공한다.
(Ⅰ)
(단, 상기 식에서, R1은 A, CF3, CH2F, CHF2또는 C2F5이고,R2및 R3는 각기 독립적으로 H, A, 탄소수가 3 내지 7인 시클로알킬기, Rh 또는 Het이고, R2및 R3는 함께 결합하여 탄소수가 4 또는 5인 알킬렌기이고, Het는 N 또는 C를 통하여 결합되는 N, O 및/또는 S원자수가 1~4인 단일고리형 또는 두고리형의 포화, 불포화 또는방향성 헤테로고리형기이고, 이 기는 Hal, CF3, A, OH, OA, SH, SA, NH2, NHA, NA2, CN, NO2및/또는 카르보닐산소로 일-, 이- 또는 삼치환되거나 또는 비치환된 기이며, A는 탄소수가 1 내지 6인 알킬기이며, Het은 F, Cl, Br 또는 I이고, Ph는 A, OA, NH2, NHA, NA2, F, Cl, Br 및/또는 CF3로 일-, 이- 또는 삼치환되거나 또는 비치환된 페닐이다).
본 발명의 화합물은 세포내 Na+/H+상호수송기의 억제제로서 작용하고 항부정맥 특성을 나타낸다.
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
Claims (8)
- 일반식(Ⅰ)으로 표시되는 4-아미노벤조일구아니딘 유도체 및 이의 생리학적으로 허용 가능한 염.(Ⅰ)(단, 상기 식에서, R1은 A, CF3, CH2F, CHF2또는 C2F|5이고,R2및 R3는 각기 독립적으로 H, A, 탄소수가 3 내지 7인 시클로알킬기, Rh 또는 Het이고, R2및 R3는 함께 결합하여 탄소수가 4 또는 5인 알킬렌기이고, Het는 N 또는 C를 통하여 결합되는 N, O 및/또는 S원자수가 1~4인 단일고리형 또는 두고리형의 포화, 불포화 또는 방향성 헤테로고리형기이고, 이 기는 Hal, CF3, A, OH, OA, SH, SA, NH2, NHA, NA2, CN, NO2및/또는 카르보닐산소로 일-, 이- 또는 삼치환되거나 또는 비치환된 기이며, A는 탄소수가 1 내지 6인 알킬기이며, Het은 F, Cl, Br 또는 I이고, Ph는 A, OA, NH2, NHA, NA2, F, Cl, Br 및/또는 CF3로 일-, 이- 또는 삼치환되거나 또는 비치환된 페닐이다).
- 제1항에 있어서, 상기한 일반식(Ⅰ)의 화합물이 다음 화합물(a) 내지 (g)인 것을 특징으로 하는 화합물 및 이들의 생리학적으로 허용 가능한 염 : (a) N-디아미노메틸렌-2-에틸-4-피페리디노-5-메틸술포닐벤조아미드; (b) N-디아미노메틸렌-2-메틸-4-피페리디노-5-메틸술포닐벤조아미드; (c)N-디아미노메틸렌-2-메틸-4-N,N-디이소프로필아미노-5-메틸술포닐벤조아미드; (d) N-디아미노메틸렌-2-메틸-4-페닐아미노-5-메틸술포닐벤조아미드; (e) N-디아미노메틸렌-2-메틸-4-(2-피리미딘일아미노)-5-메틸술포닐벤조아미드; (f) N-디아미노메틸렌-2-메틸-4-(3-클로로페닐아미노)-5-메틸술포닐벤조아미드; (g) N-디아미노메틸렌-2-메틸-4-(N′,N′-디이소프로필아미노)-5-메틸술포닐벤조아미드.
- 제1항에 따른 일반식(Ⅰ)으로 표시되는 아미노벤조일구아니딘 유도체 및 이들의 염중 하나를 제조하는 방법에 있어서, 하기 일반식(Ⅱ)으로 표시되는 화합물을 구아니딘과 반응시키거나, 또는 하기 일반식(Ⅲ)으로 표시되는 벤조일구아니딘을 하기 일반식(Ⅳ)으로 표시되는 화합물과 반응시키거나, 또는 하나 이상의 수소원자 대신에 하나 이상의 환원성 기 및/또는 하나 이상의 추가의 C-C 및/또는 C-N결합을 가지며 그밖에는 일반식(Ⅰ)과 일치하는 화합물을 환원제로 치리하거나, 또는 하나 이상의 수소원자 대신에 하나 이상의 가용매분해성기를 가지며 그밖에는 일반식(Ⅰ)과 일치하는 화합물을 가용매성분해제로 처리하거나 및/또는 생성된 일반식(Ⅰ)의 염기를 산으로 처리함으로써 이의 염중의 하나로 전환시키는 것을 특징으로 하는 제조방법.(Ⅱ)(Ⅲ)R3-R2-N-D (Ⅳ)(단, 상기 식에서, R1, R2, R3및 A는 상기에서 정의된 바와 같고, Q는 Cl, Br, OA, O-CO-A, O-CO-Ph, OH, 또는 기타 반응적으로 에스테르화된 OH기 또는 친핵적으로 쉽게 치환될 수 있는 이탈기이고, R4는 F, Cl, Br, I 또는 기타 적합한 이탈기이다).
- 제1항에 따른 일반식(Ⅰ)으로 표시되는 화합물 및/또는 이의 생리학적으로 허용 가능한 염중의 하나를 1종 이상의 고체, 액체 또는 반액체 부형제 또는 보조제와 함께 적합한 투여 형태로 만드는 것을 특징으로 하는 약제학적 제형의 제조방법.
- 제1항에 따른 일반식(Ⅰ)으로 표시되는 화합물 1종 이상 및/또는 이의 생리학적으로 허용 가능한 염중의 하나를 함유하는 것을 특징으로 하는 약제학적 제형.
- 질병 치료용 약물의 제조에 사용되는 제1항에 따른 일반식(Ⅰ)으로 표시되는 화합물 또는 이의 생리학적으로 허용 가능한 염.
- 질병의 조절에 사용되는 제1항에 따른 일반식(Ⅰ)으로 표시되는 화합물 또는 이의 생리학적으로 허용 가능한 염.
- 부정맥중, 협심증 및 경색중의 치료, 또는 상기 질병의 예방치료용 약물의 제조에 사용되는 제1항에 따른 일반식(Ⅰ)으로 표시되는 화합물.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19502644A DE19502644A1 (de) | 1995-01-28 | 1995-01-28 | 4-Amino-benzoylguanidin-Derivate |
| DE19502644.6 | 1995-01-28 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR960029319A true KR960029319A (ko) | 1996-08-17 |
| KR100521853B1 KR100521853B1 (ko) | 2006-06-16 |
Family
ID=7752517
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1019960002014A Expired - Fee Related KR100521853B1 (ko) | 1995-01-28 | 1996-01-27 | 4-아미노벤조일구아니딘유도체 |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US5739142A (ko) |
| EP (1) | EP0723963B1 (ko) |
| JP (1) | JP3770946B2 (ko) |
| KR (1) | KR100521853B1 (ko) |
| CN (1) | CN1057999C (ko) |
| AR (1) | AR002273A1 (ko) |
| AT (1) | ATE202093T1 (ko) |
| AU (1) | AU705632B2 (ko) |
| BR (1) | BR9600217A (ko) |
| CA (1) | CA2168192C (ko) |
| CO (1) | CO4700428A1 (ko) |
| CZ (1) | CZ289922B6 (ko) |
| DE (2) | DE19502644A1 (ko) |
| DK (1) | DK0723963T3 (ko) |
| ES (1) | ES2158153T3 (ko) |
| FI (1) | FI960376L (ko) |
| GR (1) | GR3036572T3 (ko) |
| HU (1) | HUP9600173A3 (ko) |
| NO (1) | NO305793B1 (ko) |
| PL (1) | PL182219B1 (ko) |
| PT (1) | PT723963E (ko) |
| RU (1) | RU2160728C2 (ko) |
| SI (1) | SI0723963T1 (ko) |
| SK (1) | SK281198B6 (ko) |
| TR (1) | TR199600064A2 (ko) |
| TW (1) | TW325463B (ko) |
| UA (1) | UA56983C2 (ko) |
| ZA (1) | ZA96629B (ko) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4328352A1 (de) * | 1993-08-24 | 1995-03-02 | Hoechst Ag | Substituierte N,N'-Di-benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
| US6277865B1 (en) * | 1997-06-27 | 2001-08-21 | Aventis Pharmaceuticals Products Inc. | Piperididinyl and N-amidinopiperidinyl derivatives |
| DE19737463A1 (de) * | 1997-08-28 | 1999-03-04 | Hoechst Marion Roussel De Gmbh | Verwendung von Inhibitoren des Natrium-Wasserstoff-Austauschers zur Herstellung eines Arzneimittels zur Behandlung von Erkrankungen, die durch Protozoen verursacht werden |
| WO2000030624A2 (en) * | 1998-11-26 | 2000-06-02 | Merck Patent Gmbh | Use of benzoylguanidines for the treatment of non-insulin-dependent diabetes mellitus |
| DE19859727A1 (de) * | 1998-12-23 | 2000-06-29 | Aventis Pharma Gmbh | Die Verwendung von Hemmern des Natrium-Wasserstoff-Austauschers zur Herstellung eines Medikaments zur Verhinderung von altersbedingten Organ-Dysfunktionen, altersbedingten Erkrankungen zur Lebensverlängerung |
| DE10023405A1 (de) * | 2000-05-12 | 2001-11-15 | Merck Patent Gmbh | Verfahren zur Herstellung von Sulfonyl-benzoylguanidinum-Salzen |
| SA04250283B1 (ar) * | 2003-09-26 | 2008-05-26 | سولفاي فارماسيتيكالز جي أم بي أتش | مشتقات من amidomethy1-substituted1-(carboxyalkyl)-cyclopentylcarbonylamino-benzazepine-N-acetic acid |
| DE102005030400A1 (de) * | 2005-06-27 | 2006-12-28 | Archimica Gmbh | Verfahren zur Herstellung von Arylaminen, Arylethern und Arylthioethern |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3929582A1 (de) * | 1989-09-06 | 1991-03-07 | Hoechst Ag | Benzoylguanidine, verfahren zu ihrer herstellung, ihre verwendung als medikament sowie sie enthaltendes medikament |
| EP0589336B1 (de) * | 1992-09-22 | 1997-01-08 | Hoechst Aktiengesellschaft | Benzoylguanidine, Verfahren zu ihrer Herstellung, sowie ihre Verwendung als Antiarrhythmika |
| DE4328869A1 (de) * | 1993-08-27 | 1995-03-02 | Hoechst Ag | Ortho-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
-
1995
- 1995-01-28 DE DE19502644A patent/DE19502644A1/de not_active Withdrawn
-
1996
- 1996-01-05 UA UA96010053A patent/UA56983C2/uk unknown
- 1996-01-19 EP EP96100763A patent/EP0723963B1/de not_active Expired - Lifetime
- 1996-01-19 DK DK96100763T patent/DK0723963T3/da active
- 1996-01-19 AT AT96100763T patent/ATE202093T1/de not_active IP Right Cessation
- 1996-01-19 DE DE59607054T patent/DE59607054D1/de not_active Expired - Lifetime
- 1996-01-19 SI SI9630328T patent/SI0723963T1/xx unknown
- 1996-01-19 PT PT96100763T patent/PT723963E/pt unknown
- 1996-01-19 ES ES96100763T patent/ES2158153T3/es not_active Expired - Lifetime
- 1996-01-22 AU AU42112/96A patent/AU705632B2/en not_active Ceased
- 1996-01-25 CO CO96003094A patent/CO4700428A1/es unknown
- 1996-01-25 BR BR9600217A patent/BR9600217A/pt not_active Application Discontinuation
- 1996-01-26 JP JP03122196A patent/JP3770946B2/ja not_active Expired - Fee Related
- 1996-01-26 CN CN96101244A patent/CN1057999C/zh not_active Expired - Fee Related
- 1996-01-26 HU HU9600173A patent/HUP9600173A3/hu unknown
- 1996-01-26 SK SK122-96A patent/SK281198B6/sk unknown
- 1996-01-26 AR ARP960101165A patent/AR002273A1/es unknown
- 1996-01-26 TR TR96/00064A patent/TR199600064A2/xx unknown
- 1996-01-26 ZA ZA96629A patent/ZA96629B/xx unknown
- 1996-01-26 PL PL96312490A patent/PL182219B1/pl not_active IP Right Cessation
- 1996-01-26 TW TW085100970A patent/TW325463B/zh active
- 1996-01-26 US US08/592,660 patent/US5739142A/en not_active Expired - Lifetime
- 1996-01-26 FI FI960376A patent/FI960376L/fi unknown
- 1996-01-26 NO NO960353A patent/NO305793B1/no not_active IP Right Cessation
- 1996-01-26 RU RU96101810/04A patent/RU2160728C2/ru not_active IP Right Cessation
- 1996-01-26 CZ CZ1996252A patent/CZ289922B6/cs not_active IP Right Cessation
- 1996-01-26 CA CA002168192A patent/CA2168192C/en not_active Expired - Fee Related
- 1996-01-27 KR KR1019960002014A patent/KR100521853B1/ko not_active Expired - Fee Related
-
2001
- 2001-09-10 GR GR20010401429T patent/GR3036572T3/el not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR890011601A (ko) | (사이클로알킬아미노)메틸렌비스(포스폰산)및 활성성분으로서 이를 함유한 의약 | |
| KR960034164A (ko) | 스틸벤 유도체 및 이를 함유하는 약제학적 조성물 | |
| KR940703806A (ko) | 20-메틸-치환된 비타민 D 유도체 (20-Methyl-Substituted Vitamin D Derivatives) | |
| KR880006193A (ko) | 피페리딘 화합물 및 그의 제조 및 용도 | |
| KR900006318A (ko) | 피페리디닐 벤즈이미다졸 | |
| DE3271269D1 (en) | Benzimidazole derivatives, process for the preparation thereof and pharmaceutical composition containing the same | |
| AU2095092A (en) | New arylethylamine compounds, processes for the preparation thereof, and pharmaceutical compositions containing them | |
| KR890011592A (ko) | 기관내 허혈병의 치료용 조성물 | |
| KR890002060A (ko) | 옥사졸리디논 화합물 | |
| KR960007592A (ko) | 신규한 피롤로카바졸 | |
| HUT57773A (en) | Process for produicng n-(aminocarbonyl)-carbamates related to physostigmine, as well as pharmaceutical compositions comprising such compounds | |
| KR960029319A (ko) | 4-아미노벤조일구아니딘 유도체 | |
| KR960007539A (ko) | 오르토-치환된 벤조산 유도체 | |
| KR910006309A (ko) | 인지질 및 인지질 유도체를 유효 성분으로 하는 항비루스성 약제 | |
| KR930016436A (ko) | 4, 13-디옥사바이사이클로[8.2.1]트리데세논유도체와 그의 제조방법, 그의 제조를 위한 중간체 및 이화합물이 함유된 약학조성물 | |
| KR960007538A (ko) | 알킬벤조일구아니딘 유도체 | |
| KR960007540A (ko) | 아릴벤조일구아니딘 유도체 | |
| NO834884L (no) | Fremgangsmaate for fremstilling av farmakologisk aktive nitroalifatiske forbindelser | |
| KR940003953A (ko) | 1. 4-벤조디옥산 유도체 | |
| KR960041154A (ko) | 플루오르 함유 벤조일구아니딘 유도체 | |
| KR970706251A (ko) | 항종양제 및 항바이러스제로서의 비스-(2-할로에틸)아미노페닐 치환된 디스타마이신 유도체(Bis-(2-haloethyl)aminophenyl substituted distamycin derivatives as antitumor and antiviral agents) | |
| ATE110721T1 (de) | 2-alkyl-3-benzoylbenzofurane und diese enthaltende pharmazeutische zusammensetzungen. | |
| KR960031442A (ko) | 페닐시클로헥실카르복스아미드의 용도 | |
| KR910016691A (ko) | 신규한 치환된-아민 화합물 및 그의 제조방법 | |
| KR970704685A (ko) | 신경이완제로서 유용한 N-치환 아자비시클로헵탄 유도체(N-Substituted Azabicycloheptane Derivatives Useful as Neuroleptics) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 19960127 |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20001208 Comment text: Request for Examination of Application Patent event code: PA02011R01I Patent event date: 19960127 Comment text: Patent Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20030422 Patent event code: PE09021S01D |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20040130 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20030422 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |
|
| J201 | Request for trial against refusal decision | ||
| PJ0201 | Trial against decision of rejection |
Patent event date: 20040421 Comment text: Request for Trial against Decision on Refusal Patent event code: PJ02012R01D Patent event date: 20040130 Comment text: Decision to Refuse Application Patent event code: PJ02011S01I Appeal kind category: Appeal against decision to decline refusal Decision date: 20050729 Appeal identifier: 2004101001729 Request date: 20040421 |
|
| J301 | Trial decision |
Free format text: TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20040421 Effective date: 20050729 |
|
| PJ1301 | Trial decision |
Patent event code: PJ13011S01D Patent event date: 20050730 Comment text: Trial Decision on Objection to Decision on Refusal Appeal kind category: Appeal against decision to decline refusal Request date: 20040421 Decision date: 20050729 Appeal identifier: 2004101001729 |
|
| PS0901 | Examination by remand of revocation | ||
| S901 | Examination by remand of revocation | ||
| GRNO | Decision to grant (after opposition) | ||
| PS0701 | Decision of registration after remand of revocation |
Patent event date: 20050830 Patent event code: PS07012S01D Comment text: Decision to Grant Registration Patent event date: 20050809 Patent event code: PS07011S01I Comment text: Notice of Trial Decision (Remand of Revocation) |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20051007 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20051010 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration | ||
| LAPS | Lapse due to unpaid annual fee | ||
| PC1903 | Unpaid annual fee |
Termination category: Default of registration fee Termination date: 20090910 |